T. Rowe Price Associates
IRMD icon

T. Rowe Price Associates’s iRadimed IRMD Stock Holding History

T. Rowe Price Associates’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$667K Buy
6,973
+789
+13% +$71.9K ﹤0.01% 2489
2026
Q1 		$596K Buy
6,184
+1,402
+29% +$140K ﹤0.01% 2370
2025
Q4 		$466K Buy
4,782
+458
+11% +$39.3K ﹤0.01% 2430
2025
Q3 		$308K Buy
4,324
+476
+12% +$31.7K ﹤0.01% 2593
2025
Q2 		$231K Buy
+3,848
New +$211K ﹤0.01% 2650

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates's IRMD Position: Q2 2026 in Review

T. Rowe Price Associates increased its iRadimed (IRMD) stake by 13% in Q2 2026, buying an estimated $71.9K and bringing the position to 6,973 shares worth $667K. The position accounts for ﹤0.01% of the portfolio, ranked #2489.

T. Rowe Price Associates first reported a position in IRMD in Q2 2025 and has held it in 5 quarters since. 213 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • T. Rowe Price Associates held 6,973 shares of iRadimed worth $667K as of Q2 2026.
  • T. Rowe Price Associates bought 789 iRadimed shares in Q2 2026, an estimated $71.9K.
  • iRadimed made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2489 holding.
  • T. Rowe Price Associates first reported a position in iRadimed in Q2 2025 and has held it in 5 quarters since.
  • 213 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.